Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBT (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed EBT for 15 consecutive years, with -$623000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 89.09% year-over-year to -$623000.0, compared with a TTM value of -$6.4 million through Sep 2025, down 588.35%, and an annual FY2024 reading of -$71000.0, up 99.56% over the prior year.
  • EBT was -$623000.0 for Q3 2025 at Fennec Pharmaceuticals, up from -$3.2 million in the prior quarter.
  • Across five years, EBT topped out at $12.9 million in Q1 2024 and bottomed at -$6.9 million in Q4 2022.
  • Average EBT over 5 years is -$2.9 million, with a median of -$3.9 million recorded in 2021.
  • Peak annual rise in EBT hit 316.58% in 2024, while the deepest fall reached 222.47% in 2024.
  • Year by year, EBT stood at -$4.1 million in 2021, then crashed by 67.8% to -$6.9 million in 2022, then soared by 62.03% to -$2.6 million in 2023, then skyrocketed by 42.67% to -$1.5 million in 2024, then surged by 58.49% to -$623000.0 in 2025.
  • Business Quant data shows EBT for FENC at -$623000.0 in Q3 2025, -$3.2 million in Q2 2025, and -$1.2 million in Q1 2025.